Disorder of Sex Development, 46,XY Clinical Trial
— GENEXPLOROfficial title:
Search for Structural Variants in Patients With Disorders of Sex Development (DSD) and Inconclusive Molecular Diagnosis GENEXPLOR-DSD
The goal of this clinical trial is to identify structural variants by Optical Genome Mapping (OGM) in the described participant population. The main questions it aims to answer are: - Identify constitutional structural variants by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive. - Identify mosaic structural variants (present in a subpopulation of somatic cells only) by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive. - Compare the diagnostic yields of OGM and of Comparative Genome Hybridization Array (CGH array) methods. - Compare the diagnostic yields of the OGM and of Whole Genome Sequencing (National Sequencing Program), only if performed. Participants will be required to: - a follow-up interview with a physician to review their own and family medical and surgical history, with a focusing on DSD. - An interview to assess their exposure to environmental pollutants during fetal life, using a validated questionnaire. - a blood test with a 5mL tube to perform optical genome mapping analysis.
| Status | Recruiting |
| Enrollment | 20 |
| Est. completion date | June 15, 2025 |
| Est. primary completion date | June 15, 2025 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 6 Months and older |
| Eligibility | Inclusion Criteria: - homogeneous XY male karyotype. - patient at least 6 months old - severe to moderate DSD (Prader 1 to 5) for which the molecular diagnosis is inconclusive after a gene panel analysis. Exclusion Criteria: - subject with a homogeneous or mosaic XX, or monosomal X karyotype. - subject with an aneuploidy. - subject with a conclusive molecular diagnosis explaining the observed DSD (i.e. carrier of a causal genotype already well characterized by functional studies) |
| Country | Name | City | State |
|---|---|---|---|
| France | University Hospital Montpellier | Montpellier |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Montpellier |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants with a constitutional structural variants detected by OGM | A structural variant, present at the constitutional state in leukocyte DNA, and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients. | Day of inclusion | |
| Secondary | Number of Participants with mosaic structural variants detected by OGM | A structural variant, present at the mosaic state in leukocyte DNA (i.e. allelic imbalance less than 0.40), and considered as likely pathogenic or pathogenic, identified by OGM in at least one of the included patients. | Day of inclusion |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04831099 -
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
|
Phase 3 |